Abstract
Pituitary adenomas are the most frequent tumors of the sellar region. The adenomas can be divided into hormone-secreting and nonfunctioning adenomas. Clinical symptoms are dependent on either the overproduction of a specific hormone, leading to typical disease states (acromegaly, Cushing’s disease, hyperprolactinemia, secondary hyperthyroidism) or compression symptoms due to tumor growth. The common compressive symptoms include visual disturbance and visual field defects, as well as pituitary insufficiencies. Headaches as an unspecific symptom are also common. Cavernous sinus syndrome with palsy of the third, fourth, or sixth cranial nerve is uncommon in the absence of apoplexy. After the diagnosis of a pituitary lesion by CT or, more frequently, MR imaging, an endocrinological assessment is necessary to identify hormone-secreting lesions as well as to rule out pituitary insufficiency. Except for prolactinomas, surgical resection is the first-line treatment for symptomatic adenomas. In case of residual disease, pharmacotherapy and/or radiotherapy may be necessary. Due to the potential complex character of pituitary adenomas, the patient care may require a multidisciplinary cooperation of family medicine, gynecology, endocrinology, ophthalmology, radiology, radiotherapy, neurology, and neurosurgery. After diagnosis of symptomatic adenomas, long-term follow-up of patients is recommended.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, Davis FG (1999) Descriptive epidemiology of primary brain and CNS tumors: results from the central brain tumor registry of the United States, 1990–1994. Neuro Oncol 1:14–25
Daly AF, Tichomirowa MA, Beckers A (2009) The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23:543–554
Buurman H, Saeger W (2006) Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol 154:753–758
Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German pituitary tumor registry. Eur J Endocrinol 156:203–216
Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–617; discussion 7–8
Caimari F, Korbonits M (2016) Novel genetic causes of pituitary adenomas. Clin Cancer Res 22:5030–5042
Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL (2002) Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J Clin Invest 109:69–78
Reincke M, Sbiera S, Hayakawa A et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47:31–38
Ronchi CL, Peverelli E, Herterich S et al (2016) Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas. Eur J Endocrinol 174:363–372
Vallar L, Spada A, Giannattasio G (1987) Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566–568
Vlotides G, Eigler T, Melmed S (2007) Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev 28:165–186
Newey PJ, Nesbit MA, Rimmer AJ et al (2013) Whole-exome sequencing studies of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 98:E796–E800
Halvorsen H, Ramm-Pettersen J, Josefsen R et al (2014) Surgical complications after transsphenoidal microscopic and endoscopic surgery for pituitary adenoma: a consecutive series of 506 procedures. Acta Neurochir 156:441–449
Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377–382
Molitch ME (2014) Nonfunctioning pituitary tumors. Handb Clin Neurol 124:167–184
Fleseriu M, Yedinak C, Campbell C, Delashaw JB (2009) Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg 110:354–358
Ludecke DK (2003) [Management of patients with non-functioning pituitary adenomas. Summary of results of an expert conference of the Hypophysis Work Group of the German Society of Endocrinology, Friedewald, 15–17 February 2002]. Med Klin (Munich) 98:616–627
Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:273–288
Nomikos P, Ladar C, Fahlbusch R, Buchfelder M (2004) Impact of primary surgery on pituitary function in patients with non-functioning pituitary adenomas—a study on 721 patients. Acta Neurochir 146:27–35
Fleseriu M, Bodach ME, Tumialan LM et al (2016) Congress of Neurological Surgeons systematic review and evidence-based guideline for Pretreatment endocrine evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E527–E529
Freda PU, Beckers AM, Katznelson L et al (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:894–904
Kuo JS, Barkhoudarian G, Farrell CJ et al (2016) Congress of Neurological Surgeons systematic review and evidence-based guideline on surgical techniques and technologies for the management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E536–E538
Lucas JW, Bodach ME, Tumialan LM et al (2016) Congress of Neurological Surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E533–E535
Murad MH, Fernandez-Balsells MM, Barwise A et al (2010) Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol 73:777–791
Webb SM, Rigla M, Wagner A, Oliver B, Bartumeus F (1999) Recovery of hypopituitarism after neurosurgical treatment of pituitary adenomas. J Clin Endocrinol Metab 84:3696–3700
Sharma ST, Nieman LK, Feelders RA (2015) Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol 7:281–293
Flitsch J, Spitzner S, Ludecke DK (2000) Emotional disorders in patients with different types of pituitary adenomas and factors affecting the diagnostic process. Exp Clin Endocrinol Diabetes 108:480–485
Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93:1526–1540
Grober Y, Grober H, Wintermark M, Jane JA Jr, Oldfield EH (2018) Comparison of MRI techniques for detecting microadenomas in Cushing’s disease. J Neurosurg 128:1051–1057
Burkhardt T, Flitsch J, van Leyen P et al (2015) Cavernous sinus sampling in patients with Cushing’s disease. Neurosurg Focus 38:E6
Ikeda H, Abe T, Watanabe K (2010) Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg 112:750–755
Alwani RA, de Herder WW, van Aken MO et al (2010) Biochemical predictors of outcome of pituitary surgery for Cushing’s disease. Neuroendocrinology 91:169–178
Flitsch J, Knappe UJ, Ludecke DK (2003) The use of postoperative ACTH levels as a marker for successful transsphenoidal microsurgery in Cushing’s disease. Zentralbl Neurochir 64:6–11
Starke RM, Reames DL, Chen CJ, Laws ER, Jane JA Jr (2013) Endoscopic transsphenoidal surgery for Cushing disease: techniques, outcomes, and predictors of remission. Neurosurgery 72:240–247; discussion 7
Trainer PJ, Lawrie HS, Verhelst J et al (1993) Transsphenoidal resection in Cushing’s disease: undetectable serum cortisol as the definition of successful treatment. Clin Endocrinol 38:73–78
Flitsch J, Ludecke DK, Knappe UJ, Saeger W (1999) Correlates of long-term hypocortisolism after transsphenoidal microsurgery for Cushing’s disease. Exp Clin Endocrinol Diabetes 107:183–189
Nieman LK, Biller BM, Findling JW et al (2015) Treatment of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:2807–2831
Boscaro M, Sonino N, Scarda A et al (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J Clin Endocrinol Metab 87:3662–3666
Beck-Peccoz P, Persani L, Mannavola D, Campi I (2009) Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 23:597–606
Onnestam L, Berinder K, Burman P et al (2013) National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 98:626–635
Rotermund R, Riedel N, Burkhardt T et al (2017) Surgical treatment and outcome of TSH-producing pituitary adenomas. Acta Neurochir 159:1219–1226
Malchiodi E, Profka E, Ferrante E et al (2014) Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. J Clin Endocrinol Metab 99:2069–2076
Laws ER, Vance ML, Jane JA Jr (2006) TSH adenomas. Pituitary 9:313–315
Jane JA Jr, Thapar K, Laws ER Jr (2001) Acromegaly: historical perspectives and current therapy. J Neurooncol 54:129–137
Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411–3418
Bush ZM, Vance ML (2008) Management of acromegaly: is there a role for primary medical therapy? Rev Endocr Metab Disord 9:83–94
Carmichael JD, Bonert VS, Mirocha JM, Melmed S (2009) The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab 94:523–527
Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301:1138–1142
Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94:3746–3756
Higham CE, Atkinson AB, Aylwin S et al (2012) Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97:1187–1193
Lim DS, Fleseriu M (2017) The role of combination medical therapy in the treatment of acromegaly. Pituitary 20:136–148
Colao A, Ferone D, Cappabianca P et al (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308–3314
Nomikos P, Buchfelder M, Fahlbusch R (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 152:379–387
Yu M, Bruns DE, Jane JA Jr et al (2017) Decrease of serum IGF-I following transsphenoidal pituitary surgery for acromegaly. Clin Chem 63:486–494
Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674
Oldfield EH, Jane JA Jr, Thorner MO, Pledger CL, Sheehan JP, Vance ML (2017) Correlation between GH and IGF-1 during treatment for acromegaly. J Neurosurg 126:1959–1966
Colao A, Ferone D, Marzullo P et al (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86:2779–2786
Lee CC, Vance ML, Lopes MB, Xu Z, Chen CJ, Sheehan J (2015) Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype. Pituitary 18:326–334
Lee CC, Vance ML, Xu Z et al (2014) Stereotactic radiosurgery for acromegaly. J Clin Endocrinol Metab 99:1273–1281
Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273
Schlechte JA (2003) Clinical practice. Prolactinoma. N Engl J Med 349:2035–2041
Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68:412–418
Ferrari CI, Abs R, Bevan JS et al (1997) Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol 46:409–413
Molitch ME (2002) Medical management of prolactin-secreting pituitary adenomas. Pituitary 5:55–65
Molitch ME, Elton RL, Blackwell RE et al (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698–705
Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518–2522
Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 331:904–909
Hamilton DK, Vance ML, Boulos PT, Laws ER (2005) Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 8:53–60
Ogiwara T, Horiuchi T, Nagm A, Goto T, Hongo K (2017) Significance of surgical management for cystic prolactinoma. Pituitary 20:225–230
Andereggen L, Frey J, Andres RH et al (2017) 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas. Endocrine 55:223–230
Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP (2015) Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18:820–830
Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117:421–428
Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255–266; discussion 255–266
Chen Y, Wang CD, Su ZP et al (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96:333–342
Tedeschi E, Caranci F, Giordano F, Angelini V, Cocozza S, Brunetti A (2017) Gadolinium retention in the body: what we know and what we can do. Radiol Med 122:589–600
Ziu M, Dunn IF, Hess C et al (2016) Congress of Neurological Surgeons systematic review and evidence-based guideline on posttreatment follow-up evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 79:E541–E543
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Flitsch, J., Taylor, D.G., Jane, J.A. (2019). Pituitary Adenomas. In: Tonn, JC., Reardon, D., Rutka, J., Westphal, M. (eds) Oncology of CNS Tumors. Springer, Cham. https://doi.org/10.1007/978-3-030-04152-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-04152-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-04151-9
Online ISBN: 978-3-030-04152-6
eBook Packages: MedicineMedicine (R0)